ANTENGENE CORP. DL-0001 Market Cap ($236.09 Million)
Market Cap & Net Worth: ANTENGENE CORP. DL-0001 (722)
ANTENGENE CORP. DL-0001 market cap. ANTENGENE CORP. DL-0001 (F:722) has a market capitalization of $236.09 Million (€201.94 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #15713 globally and #1524 in its home market, demonstrating a -3.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ANTENGENE CORP. DL-0001's stock price €0.30 by its total outstanding shares 677662132 (677.66 Million). Also see 722 cash flow metrics for how efficiently the company converts equity into cash flow.
ANTENGENE CORP. DL-0001 Market Cap History (2021–2026)
ANTENGENE CORP. DL-0001 market cap history from 2021 to 2026. Data shows change from $847.72 Million to $225.00 Million (-27.28% CAGR). Check current stock price of ANTENGENE CORP. DL-0001 for real-time trading data and today's change.
ANTENGENE CORP. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ANTENGENE CORP. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 722 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.98x
ANTENGENE CORP. DL-0001's market cap is 2.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $847.72 Million | $28.77 Million | -$655.53 Million | 29.47x | N/A |
| 2022 | $475.35 Million | $160.13 Million | -$601.49 Million | 2.97x | N/A |
| 2023 | $163.21 Million | $67.31 Million | -$581.18 Million | 2.42x | N/A |
| 2024 | $50.70 Million | $91.95 Million | -$319.25 Million | 0.55x | N/A |
| 2025 | $313.73 Million | $105.34 Million | -$239.13 Million | 2.98x | N/A |
Competitor Companies of 722 by Market Capitalization
Companies near ANTENGENE CORP. DL-0001 in the global market cap rankings as of November 4, 2026. Also see ANTENGENE CORP. DL-0001 assets under control for a full breakdown of the balance sheet.
Key companies related to ANTENGENE CORP. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ANTENGENE CORP. DL-0001 (2021–2026)
Market capitalization of ANTENGENE CORP. DL-0001 from 2021 to today. Between 2021 and today, ANTENGENE CORP. DL-0001's market cap moved from $847.72 Million to $ 225.00 Million, with a yearly change of -27.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €225.00 Million | -28.28% |
| 2025 | €313.73 Million | +518.75% |
| 2024 | €50.70 Million | -68.93% |
| 2023 | €163.21 Million | -65.67% |
| 2022 | €475.35 Million | -43.93% |
| 2021 | €847.72 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ANTENGENE CORP. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $236.09 Million USD |
| MoneyControl | $236.09 Million USD |
| MarketWatch | $236.09 Million USD |
| marketcap.company | $236.09 Million USD |
| Reuters | $236.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more